Clinical Trial Update: Single and Repeated Dose Escalation Study of GSK2838232 [Phase 1]

View source ↗

Summary

A Phase 1 single and repeated dose escalation study of GSK2838232 in HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• GSK2838232

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED